Galapagos NV
Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
Mechelen
B-2800
Tel: 32-15-34-29-00
Fax: 32-15-34-29-01
Website: http://www.galapagosgenomics.com/
595 articles about Galapagos NV
-
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
11/6/2023
Landmark Bio announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S.
-
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
11/2/2023
Galapagos NV announced its financial results for the first nine months of 2023, a year-to-date business update and its outlook for the remainder of 2023.
-
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
10/30/2023
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries.
-
Galapagos appoints Simon Sturge to its Board of Directors
9/19/2023
Galapagos NV announced that during its meeting of 19 September2 023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation.
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
8/28/2023
The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.
-
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
6/15/2023
Galapagos NV announced the appointment of Thad Huston as Chief Financial Officer and Chief Operating Officer as per 1 July 2023.
-
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
6/12/2023
Galapagos NV announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director.
-
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
6/5/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and will present previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany.
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5/23/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.
-
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
5/22/2023
Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world evidence (RWE) studies at the European League Against Rheumatism (EULAR) annual congress taking place from 31 May to 3 June 2023 in Milan.
-
Galapagos creates new subscription right plans - May 05, 2023
5/5/2023
Galapagos NV announced that its Board of Directors created 1,975,000subscription rights under new subscription rightplans for the benefit of certain members ofthe personnelof the company and its subsidiaries.
-
Galapagos announces first quarter 2023 financial results
5/4/2023
Galapagos NV announced its first quarter 2023 financial results, a year-to-date business update and its outlook for the remainder of 2023.
-
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
5/2/2023
Galapagos NV announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer.
-
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
4/26/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.
-
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
4/25/2023
Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.
-
Galapagos and NovAliX enter into an integrated drug discovery collaboration
3/30/2023
Galapagos NV (Euronext & NASDAQ: GLPG)and NovAliX today announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization.
-
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
3/23/2023
Galapagos NV publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting,to be held on Tuesday 25 April 2023, at 2:00 p.m., at the registered office of the company.
-
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
2/27/2023
Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.
-
Galapagos announces full year 2022 results and outlook for 2023
2/23/2023
Galapagos NV reports 2022 results, supported by strong adoption of Jyseleca® across Europe, and provides outlook for 2023.
-
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
2/9/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation(EBMT)-European Hematology Association (EHA)5thEuropean CAR T-cell Meeting in Rotterdam.